HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

John Mascarenhas Selected Research

Biomarkers (Surrogate Marker)

11/2023MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis.
10/2021Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis.
1/2020Hemorrhage in acute promyelocytic leukemia: Can it be predicted and prevented?
1/2018Pilot study of the antifibrotic effects of the multikinase inhibitor pacritinib in a mouse model of liver fibrosis.
1/2018Emerging drugs for the treatment of Myelofibrosis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


John Mascarenhas Research Topics

Disease

64Primary Myelofibrosis (Myelosclerosis)
01/2024 - 06/2012
35Neoplasms (Cancer)
01/2024 - 11/2010
29Polycythemia Vera
01/2024 - 05/2009
14Splenomegaly
12/2023 - 06/2012
13Essential Thrombocythemia
01/2024 - 06/2014
13Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
09/2023 - 03/2014
8Thrombosis (Thrombus)
11/2023 - 11/2015
8Thrombocytopenia (Thrombopenia)
04/2023 - 07/2012
8Cytopenia
10/2022 - 01/2013
7Fibrosis (Cirrhosis)
11/2023 - 01/2016
7Anemia
10/2023 - 01/2015
5Thrombocytosis (Thrombocythemia)
11/2023 - 07/2012
5Disease Progression
04/2023 - 03/2016
5Leukemia
12/2022 - 01/2016
5Hemorrhage
12/2022 - 01/2018
5Infections
12/2022 - 03/2014
4Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
06/2022 - 09/2012
4Hematologic Neoplasms (Hematological Malignancy)
04/2020 - 06/2012
3COVID-19
12/2022 - 10/2020
3Blast Crisis (Blast Phase)
01/2022 - 03/2011
3Hemophagocytic Lymphohistiocytosis (Hemophagocytic Syndrome)
01/2021 - 04/2020
3Myeloproliferative Disorders (Myeloproliferative Disorder)
10/2019 - 09/2013
2Sepsis (Septicemia)
12/2022 - 04/2020
2Fever (Fevers)
12/2022 - 05/2020
2Myelodysplastic Syndromes (Myelodysplastic Syndrome)
04/2021 - 09/2012
2Bone Marrow Failure Disorders
12/2017 - 03/2014
1Leukocytosis (Pleocytosis)
11/2023
1Neurologic Manifestations (Neurological Manifestations)
08/2023
1Weight Gain
01/2023
1Lymphoma (Lymphomas)
12/2022
1Bacterial Infections (Bacterial Infection)
12/2022
1Agammaglobulinemia (Hypogammaglobulinemia)
06/2022
1Residual Neoplasm
06/2022
1von Willebrand Diseases (von Willebrand's Disease)
01/2022

Drug/Important Bio-Agent (IBA)

36ruxolitinibIBA
11/2023 - 06/2012
15Janus Kinase InhibitorsIBA
12/2023 - 01/2013
1211- (2- pyrrolidin- 1- ylethoxy)- 14,19- dioxa- 5,7,26- triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa- 1(25),2(26),3,5,8,10,12(27),16,21,23- decaeneIBA
10/2023 - 01/2018
11Hydroxyurea (Hydrea)FDA LinkGeneric
11/2023 - 03/2016
9CytokinesIBA
01/2024 - 08/2011
7InterferonsIBA
01/2024 - 11/2010
7fedratinibIBA
09/2023 - 01/2020
7Phosphotransferases (Kinase)IBA
10/2021 - 01/2015
6Janus KinasesIBA
10/2023 - 01/2013
6Proteins (Proteins, Gene)FDA Link
12/2022 - 08/2011
5Biomarkers (Surrogate Marker)IBA
11/2023 - 01/2018
4Janus Kinase 2IBA
01/2022 - 11/2010
3Aspirin (Acetylsalicylic Acid)FDA LinkGeneric
11/2023 - 03/2016
3Hemoglobins (Hemoglobin)IBA
11/2023 - 01/2018
3imetelstatIBA
07/2022 - 10/2021
3anagrelide (Agrylin)FDA LinkGeneric
01/2022 - 06/2015
3RG7388IBA
01/2022 - 01/2019
3AnticoagulantsIBA
10/2021 - 01/2020
3CollagenIBA
01/2021 - 01/2016
3Histone Deacetylase InhibitorsIBA
01/2017 - 07/2012
3PanobinostatIBA
01/2017 - 07/2012
2Interferon-alpha (Interferon Alfa)IBA
11/2023 - 06/2010
2Syntex adjuvant formulationIBA
10/2023 - 01/2022
2micaIBA
12/2022 - 01/2022
2AntibodiesIBA
12/2022 - 10/2020
2Immunomodulating AgentsIBA
12/2022 - 11/2010
2Telomerase (Telomerase Reverse Transcriptase)IBA
07/2022 - 10/2021
2peginterferon alfa-2a (Pegasys)FDA Link
01/2022 - 10/2019
2venetoclaxIBA
04/2021 - 11/2020
2lestaurtinibIBA
01/2019 - 01/2015
2Janus Kinase 1IBA
01/2018 - 03/2016
2Reticulin (Reticular Fiber)IBA
09/2017 - 01/2016
2Antidepressive Agents (Antidepressants)IBA
01/2017 - 01/2017
2Thrombopoietin (c-mpl Ligand)IBA
01/2016 - 01/2013
2Transforming Growth Factors (Transforming Growth Factor)IBA
01/2016 - 02/2014
2ErythropoietinFDA Link
01/2013 - 04/2012
2ChromatinIBA
08/2011 - 11/2010
1Activin Receptors (Activin Receptor)IBA
10/2023
1activin AIBA
10/2023
1HepcidinsIBA
10/2023
1Serum Amyloid P-ComponentIBA
10/2023
1N- (cyanomethyl)- 4- (2- ((4- (4- morpholinyl)phenyl)amino)- 4- pyrimidinyl)benzamideIBA
04/2023
1Interleukin-15 (Interleukin 15)IBA
12/2022
1LigandsIBA
12/2022
1AntigensIBA
12/2022
1Testosterone CongenersIBA
12/2022
1FluoroquinolonesIBA
12/2022
1Interleukin-6 (Interleukin 6)IBA
12/2022
1Anti-Inflammatory Agents (Anti-Inflammatories)IBA
12/2022
1navtemadlin; 2- ((3R,5R,6S)- 5- (3- chlorophenyl)- 6- (4- chlorophenyl)- 1- ((S)- 1- (isopropylsulfonyl)- 3- methylbutan- 2- yl)- 3- methyl- 2- oxopiperidin- 3- yl)acetic acidIBA
11/2022
1Immunoglobulin G (IgG)IBA
06/2022
1blinatumomabIBA
06/2022
1Immunoglobulins (Immunoglobulin)IBA
06/2022
1Intravenous Immunoglobulins (IVIG)FDA Link
06/2022
1Drug CombinationsIBA
01/2022
1dimemorfan (AT 17)IBA
01/2022
1Peptides (Polypeptides)IBA
01/2022
1Interleukin-1 Receptor-Associated KinasesIBA
01/2022

Therapy/Procedure

60Therapeutics
12/2023 - 06/2010
7Induction Chemotherapy
12/2022 - 01/2016
6Drug Therapy (Chemotherapy)
09/2023 - 10/2013
4Hematopoietic Stem Cell Transplantation
12/2016 - 08/2014
3Splenectomy
12/2022 - 01/2016
2Stem Cell Transplantation
12/2023 - 06/2013
2Transplantation
12/2016 - 09/2012
1Immunotherapy
12/2022